The EPS beat is entirely from non-dilutive collaboration revenue, not operational improvement — ignore for valuation. The key catalyst is SEP-479 SAD/MAD data in Q1 2027; binary event for hypoparathyroidism thesis. Monitor SEP-631 Phase 2 strategy update and TSHR candidate selection as next catalysts.
Price Chart
Executive Summary
Septerna reported Q2 2026 financial results highlighting a net loss of $13.0M (EPS -$0.29) vs consensus of -$0.48, a 39.6% beat. Pipeline progress was steady: SEP-479 Phase 1 PK supports once-daily dosing with SAD/MAD data expected Q1 2027; SEP-631 Phase 1 data positive; TSHR NAM advancing toward candidate selection. Cash of $516.5M funds operations into 2029. Collaboration revenue of $26.7M from Novo Nordisk drove the beat, but as a clinical-stage biotech this is non-core milestone/amortization revenue — the EPS surprise is mechanical, not growth-driven.
Key Financial Metrics
Key Facts
- Net loss was $13.0M for Q2 2026 vs $24.8M in Q2 2025; EPS -$0.29 vs consensus -$0.48 (beat).
- Revenue of $26.7M from Novo Nordisk collaboration (amortization of $14.6M upfront + $0.9M milestones + $11.2M research services).
- SEP-479 Phase 1 ongoing; observed half-life ~3–4 days supports once-daily dosing; SAD/MAD data expected Q1 2027.
- SEP-631 Phase 1 results reported March 2026: well-tolerated, once-daily PK, robust skin wheal suppression; evaluating Phase 2 strategies.
- TSHR NAM program progressing toward development candidate selection for Graves' disease / thyroid eye disease.
- Cash position $516.5M; expected runway into 2029.
- R&D expenses $35.1M (up 58% YoY) and G&A $8.5M (up 23% YoY) reflecting clinical ramp.
Financial Impact
EPS beat of $0.19 vs $0.48 consensus (39.6%) driven by Novo Nordisk collaboration revenue — non-core to pipeline valuation. Cash burn rate ~$18M/quarter implies 7+ years runway.
Risk Factors
- SEP-479 Phase 1 data delayed to Q1 2027; MAD cohort extension may increase development timeline risk.
- SEP-631 Phase 2 strategy undefined — potential for pivot or failure in mast cell-driven diseases.
- Pre-revenue clinical-stage biotech with no approved products; valuation tied entirely to pipeline milestones.
- R&D spend increasing 58% YoY with no near-term revenue growth from non-collaboration sources.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3342181 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 21d ago | Press Release | $38.51 $38.69 | ▲ +0.47% | ▲ +0.69% | $38.27 (−0.62%) |
Sep 3, 2026 28d ago | 3 | $36.75 $39.55 | ▲ +7.62% | ▲ +8.83% | $38.27 (+4.14%) |
Aug 25, 2026 5w ago | 8-K | $41.30 $37.68 | ▼ −8.77% | ▼ −8.23% | $38.27 (−7.34%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 14, 2026 6w ago | Insider Cluster | $44.20 $40.52 | ▲ +8.33% | ▲ +7.14% | $38.27 (+13.42%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 12, 2026 7w ago | 144 | $45.14 $40.79 | ▲ +9.64% | ▲ +7.67% | $38.27 (+15.22%) |
Aug 10, 2026 7w ago | 8-K | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Aug 10, 2026 7w ago | Press Release | $47.76 $43.80 | ▼ −8.29% | ▼ −7.89% | $38.27 (−19.87%) |
Jul 2, 2026 13w ago | Insider Cluster | $34.00 $37.84 | ▲ +11.29% | ▲ +10.36% | $38.27 (+12.56%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access